{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:12:09Z","timestamp":1791403929046,"version":"4.3.3"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/fbp.0b013e3282f62cb2","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T15:40:47Z","timestamp":1236267647000},"page":"145-152","source":"Crossref","is-referenced-by-count":56,"title":["Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice"],"prefix":"10.1097","volume":"19","author":[{"given":"Liesbeth A.","family":"Bruins Slot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s L.","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Depoortere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archpsyc.1990.01810190015002","article-title":"Positive and negative symptoms in schizophrenia. A critical reappraisal","volume":"47","author":"Andreasen","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-HT1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assie","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"R4-6-20210202","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like versus cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacol"},{"key":"R5-6-20210202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(86)90051-8","article-title":"Major tranquilizers can be distinguished from minor tranquilizers on the basis of effects on marble burying and swim-induced grooming","volume":"126","author":"Broekkamp","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","article-title":"Effects of novel antipsychotics with mixed D2 antagonist\/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat","volume":"49","author":"Bruins Slot","year":"2005","journal-title":"Neuropharmacol"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.npp.1300262","article-title":"SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: neurochemical and electrophysiological profile","volume":"28","author":"Claustre","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0707159","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: activity in models of positive symptoms of schizophrenia","volume":"151","author":"Depoortere","year":"2007a","journal-title":"Br J Pharmacol"},{"key":"R10-6-20210202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjp.0707160","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: activity in models of cognition and negative symptoms","volume":"151","author":"Depoortere","year":"2007b","journal-title":"Br J Pharmacol"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive-compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S0924-977X(02)80381-9","article-title":"SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: in vitro and in vivo pharmacology","volume":"12","author":"Glennon","year":"2002","journal-title":"Eur Neuropsychopharm"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1092852900006908","article-title":"WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults","volume":"8","author":"Greist","year":"2003","journal-title":"CNS Spectr"},{"key":"R14-6-20210202","first-page":"20","article-title":"Refractory obsessive-compulsive disorder: state-of-the-art treatment","volume":"63","author":"Hollander","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacol"},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1254\/jphs.FP0050144","article-title":"Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder","volume":"99","author":"Matsushita","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S0924-977X(02)80374-1","article-title":"SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like actions","volume":"12","author":"McCreary","year":"2002","journal-title":"Eur Neuropsychopharm"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-3565(24)29415-5","article-title":"S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine","volume":"298","author":"Millan","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R20-6-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.09.043","article-title":"Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm","volume":"504","author":"Miyamoto","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R21-6-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R23-6-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1991.tb12392.x","article-title":"Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents","volume":"104","author":"Njung'e","year":"1991a","journal-title":"Br J Pharmacol"},{"key":"R24-6-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","article-title":"Evaluation of marble burying as a model of anxiety","volume":"38","author":"Njung'e","year":"1991b","journal-title":"Pharmacol Biochem Behav"},{"key":"R25-6-20210202","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.302.1.145","article-title":"Pharmacological evidence supporting a role for central corticotropin-releasing factor2 receptors in behavioral, but not endocrine, response to environmental stress","volume":"302","author":"Pelleymounter","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R26-6-20210202","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","article-title":"Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment","volume":"18","author":"Poyurovsky","year":"2004","journal-title":"CNS Drugs"},{"issue":"S3","key":"R27-6-20210202","first-page":"S543","article-title":"The marble burying test in mice: can its predictive validity for anxiety be improved?","volume":"15","author":"Prinssen","year":"2005","journal-title":"Eur Neuropsychopharm"},{"key":"R28-6-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","article-title":"Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder symptoms? A systematic review","volume":"82","author":"Sareen","year":"2004","journal-title":"J Affect Disord"},{"key":"R29-6-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0447.2004.00502.x","article-title":"Obsessive-compulsive disorder: a critical review of therapeutic perspectives","volume":"111","author":"Schruers","year":"2005","journal-title":"Acta Psychiatr Scand"},{"key":"R30-6-20210202","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"R31-6-20210202","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug effects. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R32-6-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1254\/jjp.90.197","article-title":"Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity, on a marble burying behavior test as an obsessive-compulsive disorder model","volume":"90","author":"Takeuchi","year":"2002","journal-title":"Jpn J Pharmacol"},{"issue":"3","key":"R33-6-20210202","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/S0924-977X(00)80318-1","article-title":"DU 127090: a highly potent, atypical dopamine receptor ligand \u2013 a putative potent full spectrum antipsychotic with low EPS potential","volume":"10","author":"Van Vliet","year":"2000","journal-title":"Eur Neuropsychopharm"},{"key":"R34-6-20210202","first-page":"72","article-title":"DU127090","volume":"4","author":"Wolf","year":"2003","journal-title":"Current Opin Invest Drugs"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0b013e3282f62cb2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:29:22Z","timestamp":1738978162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-200803000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0b013e3282f62cb2","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}